AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04717869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 2D ultrasound image collection
Study NCT04717869 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker Analysis
Description: Inflammatory and nutritional biomarker analysis
Study NCT04717869 — intervention group
Intervention type: OTHER
Intervention: Frailty Index
Description: A Frailty Index Questionnaire be completed by patients or their surrogates to determine the presence of frailty at ICU admission
Study NCT06720038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the low dose VAX-31
Description: 31 valent pneumococcal conjugate vaccine
Study NCT06720038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the mid dose VAX-31
Description: 31 valent pneumococcal conjugate vaccine
Study NCT05044832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Music
Description: Personalized music delivered during the perioperative and post-operative periods. Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit.
Study NCT04208529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: CTX001 infusion.
Study NCT06569693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS) Program
Description: MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week.
Study NCT06569693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Description: BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time they spend in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week.
Study NCT06185556 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible electroporation
Description: Percutaneous (CT-guided) irreversible electroporation of 1-3 perivascular and peribiliary colorectal liver metastasis.
Study NCT06185556 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy
Description: Stereotactic body radiotherapy (CT- or MRI-guided) of 1-3 perivascular and peribiliary colorectal liver metastases.
Study NCT06079853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PureSomni Sleep Health Product Kit
Description: PureSomni sleep health products offered: blue light blocking glasses, eye mask, nasal strips, white noise machine, lavender spray, herbal tea, ear plugs
Study NCT05630885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVC 150 mg
Description: Administered as one 150-mg tablet by mouth once a day with food.
Study NCT05630885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVC 300 mg
Description: Administered as two 150-mg tablets by mouth once a day with food.
Study NCT05630885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CVC 150 mg
Description: Administered as one 150-mg matching placebo tablets by mouth once a day with food.
Study NCT05630885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for CVC 300 mg
Description: Administered as two 150-mg matching placebo tablets by mouth once a day with food.
Study NCT05349188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Participants will be provided with a smart pill bottle containing a 4-week supply of 3 mg melatonin pills.
Study NCT06573398 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT with Sequential AG regimen +Tislelizumab+Thymalfasin
Description: Stereotactic body radiation therapy (SBRT): 30 \~ 40 Gy/5f, Week 1, Day 1 \~ Day 5, 6-8 Gy/time, once a day; 3 weeks as a cycle, for 4 cycles Tislelizumab: 200 mg, i.v., single infusion, 21 days as a cycle for 4 cycles, on Day 1 of each treatment cycle; Thymalfasin: 4.8 mg, subcutaneous injection, twice a week, on Day 1 and Day 4 of each week during Weeks 1 \~ 13; Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; Gemcitabine: 1000mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle; After 4 cycles of preoperative neoadjuvant therapy, radical surgery will be evaluated by the MDT team within 2-4 weeks after completion of chemotherapy + immunotherapy.
Study NCT05009563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Description: whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
Study NCT05009563 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET/CT
Description: whole-body F-18-fluoro-deoxy-glucose positron emission tomography/computed tomography
Study NCT04828759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-treatment
Description: The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
Study NCT04828759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places
Study NCT05349188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 0.5 mg
Description: Participants will be provided with a smart pill bottle containing a 4-week supply of 0.5 mg melatonin pills.
Study NCT05349188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose placebo pill
Description: Participants will be provided with a smart pill bottle containing a 4-week supply of cellulose placebo pills.
Study NCT05292313 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Single distal femur implant
Description: Single implant fixation
Study NCT05292313 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dual distal femur implants
Description: Dual implant fixation
Study NCT06094543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Engagement Tool
Description: 8 week daily patient education and engagement tool
Study NCT05383976 — intervention group
Intervention type: OTHER
Intervention: Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program
Description: This intervention will utilize the existing Penn Medicine CRC patient navigation program. There will be a monthly list of patients with unfilled coloscopies provided, that are risk-stratified according to the machine learning algorithm and select high-risk criteria. The navigation team will prioritize timely outreach and navigation to high-risk patients according to a script that communicates risk.
Study NCT06360198 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention was applied to the group.
Study NCT04851301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Virtual Reality
Description: Participants will be assigned to an immersive VR environment.
Study NCT04851301 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active Virtual Reality
Description: Participants will be assigned to an immersive VR environment.
Study NCT04851301 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Active Virtual Reality
Description: Participants will be assigned to an immersive VR environment.
Study NCT04851301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sham Virtual Reality
Description: Participants will be assigned to a sham VR environment without the immersive experience.
Study NCT04851301 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: sham Virtual Reality
Description: Participants will be assigned to a sham VR environment without the immersive experience.
Study NCT04851301 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham Virtual Reality
Description: Participants will be assigned to a sham VR environment without the immersive experience.
Study NCT04851301 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Participants will experience tonic pain tolerance tests without exposure to any environments.
Study NCT04851301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Participants will experience tonic pain tolerance tests without exposure to any environments.
Study NCT04975568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App and face-to-face physical therapy
Description: Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites. During the app used they will have 6 face-to-face sessions in 6 people groups with a physical Therapist in a 3 months period
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Tablet
Description: 0,5 x 100 mg tablet (50 mg caffeine).
Study NCT04975568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App physical therapy
Description: Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
Study NCT04975568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App physical therapy
Description: Patients will use an app with health tests, general information about the study, personalized HTEP based in McGill's Program after their evaluations, and several online materials related with healthcare and healthy habits linked to social media sites.
Study NCT06720038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mL of the high dose VAX-31
Description: 31 valent pneumococcal conjugate vaccine
Study NCT06720038 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mL dose of PCV20
Description: 20 valent pneumococcal conjugate vaccine
Study NCT06721455 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: Discarded blood samples will be taken from routine clinical labs drawn during and after heart surgery.
Study NCT06721273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine
Description: In intervention group women will take 150 µg daily (one tablet per day, Tavan Institute, Tehran, Iran) that will be 2 months before starting the new in vitro fertilization (IVF) cycle.
Study NCT06721273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will take a placebo tablet daily (containing white wheat flour, which is similar to iodine table in terms of size, shape, and color, Tavan Institute, Tehran, Iran) 2 months before starting the new IVF cycle.
Study NCT06721078 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer navigation effectiveness
Description: To determine the effectiveness of peer navigation on viral suppression and retention in care among adolescents living with HIV in South Africa.
Study NCT06720571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular vagal neuromodulation therapy (aVNT)
Description: The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.
Study NCT06720571 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular vagal neuromodulation therapy (aVNT)
Description: The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.
Study NCT06720753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opposite to emotion action
Description: Participants will be taught the opposite action skill from Dialectical Behavior Therapy
Study NCT06720753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIVE
Description: Participants will be taught the GIVE skill from Dialectical Behavior Therapy
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine Tablet
Description: 0,5 x 100 mg tablet (50 mg caffeine).
Study NCT06332391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise-similar cardiac pacing
Description: Cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
Study NCT06332391 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cardiac pacing
Description: Simulated (rates selected using programmer but not initiated) cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
Study NCT06721650 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Perturbation-Based Balance Training
Description: Perturbation-based balance training (PBT; or reactive balance training or perturbation training) is balance training that uses repeated, externally applied mechanical perturbations to trigger rapid reactions to regain postural stability in a safe and controlled environment
Study NCT06721650 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the selected physical therapy exercise program
Description: trunk control therapeutic exercise, static and dynamic balance treaining exercises
Study NCT06721676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve replacement in severe aortic stenosis
Description: transcatheter aortic valve replacement with A² Flex and commissural alignment technology in severe aortic stenosis
Study NCT05827224 — intervention group
Intervention type: DEVICE
Intervention: Lotrafilcon B spherical soft contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT05827224 — intervention group
Intervention type: DEVICE
Intervention: Lotrafilcon B spherical soft contact lenses with comfort additive
Description: Commercially available silicone hydrogel contact lenses
Study NCT05827224 — intervention group
Intervention type: DEVICE
Intervention: Lotrafilcon B toric soft contact lenses with comfort additive
Description: Commercially available silicone hydrogel contact lenses
Study NCT06721104 — intervention group
Intervention type: OTHER
Intervention: Dual Task
Description: The dual-task abilities of individuals will be assessed by adding motor and cognitive tasks to the 10-Meter Walk Test. The tasks given to participants are as follows:~Single Motor Task (comfortable walking): The individual is asked to walk at a normal pace, and the time is recorded.~Motor-Motor Dual Task: The individual carries a half-filled water bottle in each hand while walking, and the time is recorded.~Motor-Cognitive Dual Task (mental): The individual counts backward from 10 in increments of one while walking, and the time is recorded.~Motor-Cognitive Dual Task (memory): The individual is asked to recall three previously mentioned words while walking, and the time is recorded.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Hydrochloride Capsels
Description: 1 x 20 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion Hydrochloride Capsels
Description: 1 x 20 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide Capsels
Description: 1 x 0,05 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repaglinide Capsels
Description: 1 x 0,05 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Capsels
Description: 1 x 10 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flurbiprofen Capsels
Description: 1 x 10 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 10 MG
Description: 1 x 10 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole 10 MG
Description: 1 x 10 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan Oral Solution
Description: 5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan Oral Solution
Description: 5,0 ml of 2 mg/ml oral solution (10 mg dextromethorphan).
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: 0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam oral solution
Description: 0,5 ml of 2 mg/ml oral solution (1,0 mg midazolam).
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin tablets
Description: 1 x 10 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin tablets
Description: 1 x 10 mg tablet.
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x placebo tablets in the Placebo Phase/Arm
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: 2 x 25 mg tablets
Study NCT06566794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 1 x 50 mg tablet (three times daily for three days)
Study NCT06563973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk odor
Description: One hour before feeding time, 2 cc of breast milk was dripped onto a sterile sponge and placed inside the baby's incubator, close to the baby's nose (3 cm).
Study NCT06563973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
Study NCT06563973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pacifier
Description: To support oral feeding, a pacifier was given for 3 minutes one hour before feeding time and for 2 minutes 10 minutes before feeding time.
Study NCT06125964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity-Based Goals
Description: On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Intensity-based goals ask participants to maintain a target heart rate range during physical activity based on age-adjusted heart rate (HR) max. Goals progressively increase from 55% to 60% HR max across two weeks. Research staff will show participants how to monitor their heart rate using their Fitbit Versa. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on heart rate (intensity-based goals only) and exercise duration.